Fluorets

Drug Overview

Fluorets belong strictly to the Ophthalmology Drug Category. Officially classified as a Diagnostic Dye, this medical product functions as an essential, specialized diagnostic agent. Unlike a pharmaceutical BIOLOGIC or a VEGF INHIBITOR used as a TARGETED THERAPY to chemically alter cellular disease pathways, this compound relies on physical and optical properties. It is utilized by eye care professionals to vividly visualize the structural integrity of the ocular surface, assess tear film stability, and ensure the precise fitting of specialized contact lenses.

• Generic Name: fluorescein sodium ophthalmic strips
• US Brand Names: Fluorets, Bio Glo, GloStrips, Fluor-I-Strip
• Route of Administration: Topical Ophthalmic Strips (manufactured as sterile, single-use, PRESERVATIVE-FREE paper applicators to eliminate clinical cross-contamination).
• FDA Approval Status: FDA-Approved
  
  Find out how Fluorets (fluorescein sodium strips) provide a safe and sterile diagnostic dye solution for comprehensive routine eye exams.

What Is It and How Does It Work? (Mechanism of Action)

Fluorescein sodium is a highly water-soluble, non-toxic, intensely fluorescent organic dye. It does not numb, biologically treat, or structurally alter the eye. Instead, it responds dynamically to specific wavelengths of light to reveal microscopic anatomical details.

Physiologically, the outermost protective layer of a healthy cornea (the epithelium) is packed with tightly joined, lipid-rich (fat-soluble) cells. Because fluorescein is water-soluble, a healthy, intact corneal epithelium actively repels the dye, preventing it from penetrating deeper into the eye. However, when this epithelial barrier is compromised by a scratch, an infectious ulcer, or severe dryness, the tight cellular junctions are broken. This exposes the underlying layer of the cornea (the stroma), which is hydrophilic (water-loving). When the dye is introduced, it immediately penetrates the structural break and pools within the exposed stroma.

During an examination, the clinician illuminates the eye with a cobalt blue light (emitting at approximately 465 to 490 nanometers). The pooled fluorescein absorbs this blue light energy and emits a brilliant, glowing yellow-green fluorescence (520 to 530 nanometers). Furthermore, the dye mixes with the patient’s natural tear film, creating a glowing fluid layer that highlights dry spots or the physical clearance between a rigid contact lens and the cornea.

FDA-Approved Clinical Indications

• Primary Indication: Fluorescein sodium strips for eye exams. This specifically includes corneal staining to detect epithelial defects such as traumatic abrasions, infectious ulcers, and foreign bodies.
• Other Approved & Off-Label Uses: Tear film break-up time (TBUT) evaluation for diagnosing Dry Eye Disease (DED), precision fitting of rigid gas permeable (RGP) or scleral contact lenses, and Seidel testing to detect aqueous fluid leaks following ocular trauma or surgery.

Primary Ophthalmology Indications clearly elaborated:

• Preserving visual acuity: By vividly illuminating microscopic foreign bodies, rust rings, or early viral/bacterial ulcers, it enables physicians to initiate vision-saving medical or surgical treatments immediately.
• Stabilizing the ocular surface: By allowing clinicians to quantify tear film break-up time (TBUT), it accurately diagnoses the severity of Dry Eye Disease, guiding therapy to restore the protective tear film.
• Managing intraocular pressure: When used in conjunction with a topical anesthetic drop, the dye highlights the fluid menisci required to accurately measure intraocular pressure using Goldmann applanation tonometry.

Dosage and Administration Protocols

Fluorets are administered exclusively by an eye care professional in a clinical setting. The dye is impregnated into the tip of a sterile paper strip.

Specific Instructions for Administration: The clinician will place one or two drops of sterile saline (or a topical anesthetic) onto the orange, dye-impregnated tip of the strip to activate it. The patient is instructed to look upward. The moistened tip is then gently tapped against the inside of the lower eyelid (the palpebral conjunctiva). The patient is asked to blink naturally several times to distribute the dye evenly across the tear film.

Dose Adjustments: No dose adjustments are required for elderly or pediatric patients. However, this dye must not be used while soft, hydrophilic contact lenses are on the eye, as the water-soluble dye will permanently stain the prosthetic lens matrix.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Current clinical data (2020-2026) reinforces the unparalleled efficacy of fluorescein strips as a frontline diagnostic tool. In clinical trials evaluating acute ocular trauma triage, fluorescein staining demonstrated a sensitivity of over 98% in detecting microscopic epithelial defects that were entirely invisible under standard white light examination. This highly accurate detection rate is crucial in preventing misdiagnoses that could lead to severe bacterial keratitis.

In managing chronic ocular surface disease, precise numerical data validates its utility. A normal tear film break-up time (TBUT) is recorded when the fluorescein dye remains perfectly dispersed over the cornea for more than 10 seconds. Research confirms that a TBUT consistently measuring less than 5 to 7 seconds correlates strongly with severe evaporative Dry Eye Disease. By providing exact, quantifiable measurements, this diagnostic agent directly guides the successful implementation of surface-stabilizing treatments.

Safety Profile and Side Effects

There is NO Black Box Warning associated with the use of Fluorets ophthalmic strips.

Common Side Effects (>10%):

• Temporary yellowish-orange discoloration of the skin around the eyelids or the tears running down the cheek.
• Transient blurred vision immediately following the application as the dye mixes with and thickens the tear film.
• Mild, fleeting physical awareness or stinging when the paper strip touches the inside of the eyelid.

Serious Adverse Events:

• Hypersensitivity reactions or localized allergic contact dermatitis (exceedingly rare with topical application).
• Iatrogenic bacterial infections, such as endophthalmitis. However, this risk is virtually eliminated because Fluorets are manufactured as PRESERVATIVE-FREE, individually wrapped, single-use sterile strips, preventing the cross-contamination historically associated with multi-use liquid dye bottles.

Management Strategies: Clinicians mitigate risks by exclusively using the sterile strips for a single patient and immediately discarding them. Patients are provided with tissues to dab excess tears to prevent temporary skin staining. Any highly unusual signs of sudden itching or severe eyelid swelling post-exam are treated with topical antihistamines or cold compresses.

Research Areas

In the 2020-2026 research landscape, generalized research is actively exploring the integration of Artificial Intelligence (AI) and automated machine learning algorithms with fluorescein slit-lamp photography. Clinical trials are assessing how AI can objectively grade the precise density and exact pattern of corneal fluorescein staining. This aims to eliminate human subjectivity when determining the precise severity of Dry Eye Disease or analyzing the clearance of complex scleral contact lenses.

Additionally, in Severe Disease & Surgical Integration, specialized intraoperative techniques utilize highly concentrated fluorescein during complex full-thickness corneal transplants (penetrating keratoplasty). Surgeons use the dye to perform a microscopic Seidel test, definitively confirming the water-tight integrity of surgical sutures before the patient leaves the operating table, thereby preventing post-operative pressure drops or blinding internal infections.

Disclaimer: The research findings and emerging applications described in the “Research Areas” section are currently in exploratory, preclinical, or early clinical investigation phases and are not yet established as standard clinical practice or applicable to routine professional medical use. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: A standard Baseline Visual Acuity test must be recorded prior to applying any dye, as the dye can temporarily blur vision.
• Ocular Imaging: Slit-lamp photography using a specialized cobalt blue filter and a yellow barrier filter is frequently utilized to capture high-contrast images of the glowing dye for the medical record.
• Specialized Testing: Tear film break-up time (TBUT) to evaluate the lipid layer, and Seidel testing to check for traumatic microscopic eye perforations.
• Screening: Clinicians must confirm the patient is not currently wearing soft contact lenses to prevent irreversible lens staining.

Monitoring and Precautions

• Vigilance: Clinical staff must monitor the patient for any signs of an allergic reaction, though topical allergies to this specific compound are exceptionally rare.
• Lifestyle: Once the exam is complete, patients can immediately resume normal visual tasks and lifestyle activities, provided their eyes were not concurrently dilated.
• “Do’s and Don’ts” list:
  • DO blink naturally and gently after the dye is applied; forcefully squeezing your eyes shut will push the diagnostic dye out onto your cheeks.
  • DO use a tissue to lightly dab the corners of your eyes, as the temporary yellow tint in your tears is normal.
  • DON’T insert soft contact lenses into your eyes for at least 1 to 2 hours after the exam, allowing your natural tears to completely flush the residual dye away.
  • DON’T rub your eyes vigorously during or immediately after the diagnostic procedure.

Legal Disclaimer

This medical guide is provided for educational and informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. The information contained within this document is not intended to replace a personalized consultation with a qualified medical practitioner. Always consult your ophthalmologist or specialized healthcare provider before starting, changing, or stopping any medication or clinical treatment plan.